Sjögren Disease

Sjögren disease is a chronic autoimmune disease in which lymphocytic infiltration of the exocrine glands — principally the lacrimal and salivary glands — progressively impairs their secretory function, producing the classic sicca (dryness) complex of keratoconjunctivitis sicca and xerostomia. But the underlying process is not confined to the glands: B-cell hyperactivation, autoantibody production (antinuclear antibodies, rheumatoid factor, and — most specifically — anti-Ro/SSA and anti-La/SSB), and an "autoimmune epithelitis" affecting epithelial cells well beyond the exocrine glands make this a genuinely systemic disease, with roughly half of patients developing extraglandular manifestations at some point in their disease course.^[1] This systemic character is exactly why the disease was recently renamed from "Sjögren syndrome" to Sjögren disease in current British and American guideline language — a syndrome implies a secondary symptom complex; a disease is the primary process itself.^[2]

The disease occurs in two forms. Primary Sjögren disease arises on its own, without another defined connective tissue disease. Secondary Sjögren disease occurs in a patient who already has another autoimmune connective tissue disease — most often rheumatoid arthritis, and also systemic lupus erythematosus or systemic sclerosis — layered on top of it; roughly a third of patients with rheumatoid arthritis and a comparable proportion of patients with lupus develop secondary sicca features meeting Sjögren criteria over the course of their disease.^[1] The distinction matters clinically: secondary disease is managed within the framework of the primary connective tissue disease and its own therapy, while primary disease stands on its own and needs its own coordinated rheumatology-led care plan.

Sjögren disease is common enough that pharmacists encounter it regularly, and it disproportionately affects women — by a ratio of roughly 9:1 — with peak onset in the fourth through sixth decades of life, though it occurs at any age, including in children and adolescents as juvenile Sjögren disease (see Special Populations).^[1] The Sjögren's Society of Canada estimates the disease affects roughly 1% of Canadians — more than 430,000 people — and remains widely underdiagnosed, with the average time from symptom onset to diagnosis reported at up to several years.^[3] This chapter deliberately does not re-cover the general symptomatic management of dry eyes and dry mouth — artificial tears, saliva substitutes, fluoride protocols, environmental measures — which is covered in full in this platform's Dry Eyes and Dry Mouth chapters and applies identically regardless of the underlying cause of sicca symptoms. What follows is specific to the disease itself: how it is classified and diagnosed, the extraglandular manifestations that distinguish it from simple dryness, and its disease-specific pharmacotherapy.

The sicca complex — present, but not the whole picture

Most patients present with the gradual onset of dry eyes (grittiness, burning, a foreign-body sensation) and dry mouth (difficulty with dry foods, a need to sip water constantly, altered taste) — see this platform's Dry Eyes and Dry Mouth chapters for the full symptom and examination detail, which applies identically here. What distinguishes Sjögren disease from other causes of sicca symptoms is what comes with it.

The systemic layer patients often do not volunteer

Ask directly, because patients frequently do not connect these symptoms to their dry eyes and dry mouth on their own:

• Fatigue — profound, often disproportionate to objective disease activity, and one of the most disabling and difficult-to-treat features of the disease; it is one of three symptoms (alongside dryness and pain) that EULAR's management framework treats as a core triad requiring its own explicit attention.^[4]
• Arthralgia and inflammatory arthritis — typically a symmetric, small-joint polyarthralgia or non-erosive arthritis resembling early rheumatoid arthritis in distribution, but without the erosive, deforming joint damage rheumatoid arthritis eventually causes.
• Dryness beyond the eyes and mouth — dry skin (xerosis), vaginal dryness, dry nose and throat, and reduced exocrine pancreatic secretion in some patients.
• Raynaud phenomenon, salivary or lacrimal gland swelling, and low-grade fever.

Primary vs. secondary presentation

Juvenile Sjögren disease presents differently

Children and adolescents with Sjögren disease often present with recurrent parotid gland swelling (recurrent parotitis) rather than the classic adult sicca complex, and frequently do not meet the adult classification criteria described in Assessment and Diagnosis — see Special Populations.^[2]

• Female sex — the single strongest demographic risk factor, with a female-to-male ratio of roughly 9:1.^[1]
• Age — onset peaks in the fourth through sixth decades, though the disease occurs at any age, including childhood.^[1]
• An existing connective tissue disease — rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis are the classic associations that define secondary Sjögren disease; a patient with any of these diagnoses who develops new sicca symptoms should be evaluated for secondary Sjögren disease rather than assumed to have simple age- or medication-related dryness.^[1]
• Genetic susceptibility — specific HLA class II alleles (HLA-DR and HLA-DQ variants) are associated with increased risk, consistent with the disease's autoimmune, antibody-driven pathophysiology.^[1]
• A first-degree relative with Sjögren disease or another autoimmune disease — family clustering of autoimmune disease is a recognized, if non-specific, risk factor.
• Environmental and viral triggers — Epstein-Barr virus and other viral infections have long been hypothesized as potential triggers in genetically susceptible individuals, though no single causative environmental exposure has been firmly established.^[1]

The pathophysiology, briefly

Sjögren disease is fundamentally a disease of lymphocytic infiltration and B-cell hyperactivation. CD4-positive T cells and B cells infiltrate the lacrimal and salivary glands, forming the focal lymphocytic aggregates that define the disease on minor salivary gland biopsy (see Assessment and Diagnosis).^[5] Glandular destruction alone does not fully explain the degree of secretory dysfunction seen clinically — an "autoimmune epithelitis," in which the glandular epithelial cells themselves become activated and dysfunctional independent of how much tissue has actually been destroyed, is now understood to contribute meaningfully to symptoms.^[1] The same B-cell hyperactivation drives the autoantibody production (ANA, rheumatoid factor, and — most disease-specific — anti-Ro/SSA and anti-La/SSB) used in diagnosis, and, when chronic and unchecked, can progress toward the clonal B-cell expansion that underlies this disease's genuinely elevated lymphoma risk — see Red Flags and Refer.^[1]

The 2016 ACR/EULAR classification criteria

Diagnosis (formally, classification for research and clinical purposes) uses the jointly developed American College of Rheumatology/European League Against Rheumatism criteria, built from three international patient cohorts.^[5] They apply to any patient who meets the inclusion criterion — at least one symptom of ocular or oral dryness (using the same case-history questions as the four-question dry-eye screen used in this platform's Dry Eyes chapter, or oral equivalents), or a positive systemic-disease-activity screen — and who has none of the following exclusion criteria: history of head and neck radiation treatment, active hepatitis C infection (confirmed by PCR), AIDS, sarcoidosis, amyloidosis, graft-versus-host disease, or IgG4-related disease, all of which can independently cause a sicca-like picture and must be ruled out first.^[5]

Among patients meeting the inclusion criterion with no exclusion criterion present, classification requires a weighted sum of ≥4 across five objective items:

^[5] Either a positive biopsy or positive anti-Ro/SSA serology is required to corroborate the autoimmune nature of the disease — a patient cannot reach the threshold of 4 from the three minor (1-point) items alone.^[5] This is also why the criteria recognize genuinely systemic presentations: a patient with strong extraglandular disease and B-cell activation markers but without prominent ocular or oral symptoms can still be appropriately classified.^[5]

Serology and bloodwork

Anti-Ro/SSA antibodies are present in roughly 70% of patients and anti-La/SSB antibodies in roughly 40%; antinuclear antibody and rheumatoid factor are also frequently positive, reflecting the disease's B-cell-driven, hypergammaglobulinemic character.^[3] Complement levels (C3, particularly C4), serum immunoglobulins and serum protein electrophoresis, and cryoglobulins are checked both as part of the initial workup and as ongoing lymphoma-risk stratification — see Red Flags and Refer and Monitoring and Follow-Up.^[2][6]

The minor salivary gland (lip) biopsy

A labial salivary gland biopsy is the more invasive of the two 3-point criteria items, performed under local anesthetic through a small incision in the lower lip, evaluated by a pathologist for focal lymphocytic sialadenitis (dense aggregates of at least 50 lymphocytes per 4 mm² of glandular tissue). Beyond its diagnostic weight, the biopsy also provides prognostic information relevant to lymphoma risk (a high focus score is itself a lymphoma predictor) and can be genuinely useful even in patients who are anti-Ro/SSA seronegative but strongly clinically suspected.^[2]

Baseline extraglandular screening

Beyond the classification workup itself, a comprehensive baseline evaluation typically includes thyroid function testing, liver function tests, tissue transglutaminase IgA (screening for associated celiac disease), immunoglobulins and serum protein electrophoresis, complement levels, serum bicarbonate (screening for renal tubular acidosis — see Recognize the Condition and Special Populations), creatine kinase, and vitamin D, repeated periodically as clinically indicated.^[2] This baseline is what makes it possible to recognize a genuinely new extraglandular manifestation later, rather than discovering it only once it has become clinically severe.

• Coordinate — do not duplicate — the general sicca management already covered in this platform's Dry Eyes and Dry Mouth chapters, while adding what is genuinely specific to this disease.
• Treat the disabling fatigue, arthralgia, and inflammatory pain that define the systemic symptom triad alongside dryness, rather than treating this as purely an ocular/oral condition.
• Recognize and appropriately treat extraglandular/systemic manifestations — interstitial lung disease, renal tubular acidosis, peripheral neuropathy, cutaneous vasculitis — that a sicca-only view will miss entirely.
• Use hydroxychloroquine and other immunomodulatory therapy with an honest understanding of their actual evidence base, rather than assuming they will fix dryness itself.
• Reserve rituximab and other biologic/immunosuppressive therapy for genuinely severe, refractory, or organ-threatening disease — not as a routine escalation for sicca symptoms that have not responded to standard measures.
• Screen for, recognize, and act promptly on lymphoma red flags at every encounter — this is a genuinely high-yield, easily missed pharmacist contribution given how much contact these patients have with the pharmacy.
• Coordinate care explicitly across rheumatology (the usual lead), dentistry, ophthalmology, and any organ specialist a given manifestation requires, rather than allowing any one piece of a complex, multisystem disease to be managed in isolation.

Layer 1 — sicca symptoms (cross-reference, not duplicated here)

Manage exactly per this platform's Dry Eyes and Dry Mouth chapters: preservative-free artificial tears/saliva substitutes as first-line for every patient, escalating per each chapter's own tiered framework. Where this disease adds something specific: pilocarpine is Health Canada-approved by name for Sjögren-associated xerostomia (alongside radiation-induced xerostomia) and is a genuine treatment trial — not merely a comfort measure — in a patient with residual salivary gland tissue; see Pharmacologic Treatment Options and the Dry Mouth chapter for full dosing and safety detail, which is not repeated here.

Layer 2 — fatigue, arthralgia, and systemic symptoms

First discussion point hydroxychloroquine, typically 200-400 mg/day, is the guideline-endorsed first-line agent for troublesome fatigue, arthralgia, and other systemic symptoms — but set expectations honestly. The rigorous, placebo-controlled JOQUER trial found hydroxychloroquine produced no significant improvement in dryness, fatigue, or pain scores over 24 weeks, and current guidelines still recommend a defined 6-12 month trial for systemic symptoms on the strength of extrapolated experience from lupus and rheumatoid arthritis, open-label experience, and expert consensus rather than confirmatory placebo-controlled trial evidence in Sjögren disease specifically.^[7][2] This is a genuinely useful, honest counseling point: hydroxychloroquine is reasonable to try, but a patient should not be promised it will fix their dry eyes or dry mouth, and if it is not helping after a genuine 6-12 month trial, that is an expected outcome, not necessarily a treatment failure requiring immediate escalation.^[7][2]

If hydroxychloroquine alone is insufficient for inflammatory arthritis/arthralgia methotrexate is added, either alone or in combination with hydroxychloroquine, following the same stepped approach used in rheumatoid arthritis; a short-term NSAID or a brief, low-dose corticosteroid course is a reasonable bridge for a genuine inflammatory flare while a longer-acting agent takes effect, but is not intended for routine, indefinite use.^[8][2]

Layer 2, escalated — organ-threatening extraglandular disease

Severe, refractory, or organ-threatening disease — cryoglobulinemic vasculitis, clinically significant interstitial lung disease, severe inflammatory arthritis refractory to conventional therapy, or lymphoma-associated disease — is where rituximab and other biologic/conventional immunosuppressive agents genuinely belong. This is the single most important nuance in this whole chapter: neither American nor European guidelines recommend biologic therapy, including rituximab, as routine treatment for sicca symptoms.^[8][2] The pivotal TEARS randomized trial of rituximab in primary Sjögren disease missed its primary patient-reported symptom endpoints, even though objective measures (unstimulated salivary flow, salivary gland ultrasound echostructure) improved more with rituximab than placebo — a real biological signal that has not translated into a routine, guideline-endorsed indication for ordinary dryness.^[9] See Pharmacologic Treatment Options and Drug Tables for the specific organ-manifestation-by-manifestation regimens.

• The full sicca-management protocol in this platform's Dry Eyes and Dry Mouth chapters applies without modification — hydration, xylitol/sugar-free salivary stimulation, humidification, moisture-chamber eyewear, fluoride, and dental/eye surveillance intervals are not repeated here; follow those chapters directly.
• An individualized, holistic review for fatigue — activity planning, prioritizing, and pacing; sleep quality; and general lifestyle factors — is a genuine, guideline-recommended intervention in its own right, not simply "counsel the patient to rest more."^[2]
• Structured exercise — supervised resistance training, walking programs, cardiovascular exercise, and Pilates-based programs have all shown improvement in fatigue and general well-being in small studies, and exercise is considered safe in this population; this is worth actively recommending rather than assuming a fatigued patient should avoid exertion.^[2]
• Smoking cessation — smoking worsens both sicca symptoms and the vascular component of the disease, and is a modifiable risk factor worth addressing directly.
• Sun protection — relevant given the cutaneous manifestations (photosensitive annular erythema, and the vasculitic purpura discussed in Red Flags and Refer) some patients develop.
• Vaccination planning before immunosuppression begins — pneumococcal and influenza vaccination, and confirmation of routine immunization status, are best addressed before starting methotrexate, rituximab, or another immunosuppressive agent rather than after, since vaccine response is blunted once B- or T-cell-directed therapy is underway; see Special Populations and Monitoring and Follow-Up for the rituximab-specific hepatitis B screening point.
• Coordinated multidisciplinary follow-up — rheumatology as the usual lead, with dentistry and ophthalmology on a roughly 6-month cycle (per the Dry Mouth chapter) and any relevant organ specialist (pulmonology, nephrology, neurology, hematology) added as extraglandular manifestations arise — is itself a core part of management, not an administrative afterthought.
• Patient support and education — the Sjögren's Society of Canada provides Canadian patient-facing education, support resources, and community connection that many newly diagnosed patients find genuinely valuable given how commonly this disease goes unrecognized for years before diagnosis.^[3]

Pregnancy

The central pregnancy-specific concern in Sjögren disease is not the sicca symptoms themselves but the fact that anti-Ro/SSA and anti-La/SSB antibodies cross the placenta and carry a risk of neonatal lupus syndrome and, most seriously, fetal congenital heart block — a risk shared with anti-Ro/La-positive lupus patients and not unique to Sjögren disease, but relevant to essentially every Sjögren patient of childbearing age given how commonly these antibodies are present. A confirmed anti-Ro/SSA or anti-La/SSB-positive patient who is pregnant or planning pregnancy needs a coordinated high-risk obstetric and rheumatology plan with serial fetal echocardiographic monitoring. Hydroxychloroquine is specifically recommended to continue (or start) through pregnancy in anti-Ro-positive patients — evidence from the PATCH study supports a reduction in congenital heart block risk — and is recommended in subsequent pregnancies for a patient who has already had a child affected by congenital heart block.^[2] Methotrexate, mycophenolate mofetil, and cyclophosphamide are all teratogenic and must be stopped well before conception with the prescriber's guidance, switching to a pregnancy-compatible regimen in advance rather than at the point pregnancy is confirmed. Data on rituximab in pregnancy are limited; it is generally avoided unless the clinical situation genuinely requires it, since third-trimester exposure can cause detectable B-cell depletion in the neonate.

Breastfeeding

Hydroxychloroquine is generally considered compatible with breastfeeding. Methotrexate, mycophenolate mofetil, and cyclophosphamide are not compatible and require the same advance planning as in pregnancy. Confirm the specifics of any agent against its own Drug Database monograph before advising a nursing patient.

Pediatrics — juvenile Sjögren disease

Children and adolescents with Sjögren disease often present with recurrent parotid gland swelling rather than the adult sicca complex, and frequently do not meet the adult 2016 ACR/EULAR classification criteria described in Assessment and Diagnosis, which were derived and validated in adult cohorts.^[2] Recurrent parotitis in juvenile disease is typically managed with an escalating approach — a short course of NSAIDs or oral steroids combined with gentle massage, then saline or steroid gland washouts for recurrent episodes — with anti-B-cell targeted therapy (rituximab) reserved for selected, refractory cases and used off-label from as young as 3-6 years of age in some published pediatric experience.^[2] Pediatric care should be coordinated with a pediatric rheumatologist experienced in this disease rather than managed using adult-derived assumptions.

Older adults

Polypharmacy is common in this population, and the anticholinergic-burden principles from the Dry Mouth and Dry Eyes chapters apply directly — review the full medication list for agents that will worsen the patient's baseline sicca symptoms. Renal and hepatic function should be confirmed before initiating or continuing methotrexate or other systemically active immunomodulatory therapy, and dose-adjusted accordingly.

Renal impairment, including distal renal tubular acidosis

Distal (type 1) renal tubular acidosis, from lymphocytic infiltration of the renal tubulointerstitium, is the most common renal manifestation of Sjögren disease and can present with hypokalemia (occasionally severe enough to cause muscle weakness or paralysis — see Red Flags and Refer), nephrocalcinosis, kidney stones, and impaired urinary concentrating ability. Potassium citrate is the preferred correction for the combined acidosis and hypokalemia (see Pharmacologic Treatment Options); confirm renal function before and during use, since overcorrection risks hyperkalemia, particularly if renal function is also impaired. Methotrexate and other renally cleared agents need standard renal dose adjustment or avoidance in significant impairment — confirm against the product's own Drug Database monograph and current renal function.

Before starting rituximab or another biologic/immunosuppressive agent

Confirm hepatitis B status before starting rituximab — B-cell depletion carries a real risk of hepatitis B reactivation in a patient with chronic or resolved infection, and this needs to be screened for and managed (with antiviral prophylaxis where indicated) before the first dose, not discovered afterward. Confirm vaccination status is up to date beforehand as well, since vaccine response is blunted once B-cell-depleting therapy is underway — see Non-Pharmacologic Management.

• Maintain the coordinated care cycle — rheumatology as the usual lead, with dentistry and ophthalmology follow-up roughly every 6 months as established in the Dry Mouth chapter, plus any organ specialist a given extraglandular manifestation requires.^[3]
• Screen for lymphoma red flags at every single encounter, not just at diagnosis — new or changed salivary gland swelling, new palpable purpura, new lymphadenopathy, or new B symptoms (fever, night sweats, weight loss) — and act on any positive finding per Red Flags and Refer rather than deferring it to the next scheduled rheumatology visit.^[2][6]
• Hydroxychloroquine: confirm ophthalmologic retinopathy monitoring is current — a baseline eye exam within the first year of starting, then annual screening beginning after 5 years of use (sooner if additional risk factors, such as renal impairment or a higher weight-based dose, are present) — for as long as the drug is continued, since retinopathy risk does not diminish just because a patient has tolerated the drug well for years.
• Methotrexate: standard monitoring — complete blood count, liver enzymes, and renal function at the intervals used for methotrexate in rheumatoid arthritis — plus confirmation that folic acid co-supplementation is actually being taken.
• Rituximab and other biologic/immunosuppressive therapy: confirm hepatitis B status and vaccination planning were addressed before the first dose (see Special Populations), and monitor for infection and, with repeated rituximab courses, hypogammaglobulinemia.
• Reassess the fatigue-arthralgia-pain triad and overall systemic symptom burden at every visit, not only sicca symptoms — this is exactly the layer a purely dry-eye/dry-mouth-focused review will miss.^[4]
• Set — and periodically reconfirm — realistic expectations around hydroxychloroquine: it is reasonable to continue for systemic/fatigue benefit even when it has not measurably helped dryness, and conversely it is reasonable to discuss stopping it if it has not helped after a genuine 6-12 month trial and no systemic benefit is apparent either.^[7]

1. Sicca symptoms not adequately controlled with standard measures despite genuine residual gland function: follow the Dry Eyes/Dry Mouth chapters' own treatment-failure pathways (sialogogue titration, cyclosporine/lifitegrast, punctal occlusion) — do not escalate to rituximab or another systemic immunosuppressive agent for sicca symptoms alone; the evidence base does not support that step.^[9][8]
2. No improvement in fatigue or systemic symptoms after a genuine 6-12 month hydroxychloroquine trial: this is an expected outcome for a meaningful proportion of patients given the trial evidence — reassess whether the drug is still worth continuing for any other reason (e.g., mild benefit reported subjectively, or its use in a patient who also has overlapping lupus-spectrum features) rather than assuming a dosing or adherence problem.^[7]
3. Inflammatory arthralgia/arthritis not controlled on hydroxychloroquine alone: add or switch to methotrexate, following the same stepped approach used in rheumatoid arthritis, with an NSAID or brief corticosteroid course as a bridge.^[8]
4. A genuine organ-threatening extraglandular manifestation is identified (significant interstitial lung disease, cryoglobulinemic vasculitis, severe refractory arthritis, severe sensory ataxic neuropathy): this is exactly the situation where rituximab, mycophenolate mofetil, azathioprine, cyclophosphamide, IVIG, or colchicine — matched to the specific manifestation per Pharmacologic Treatment Options — become appropriate, coordinated with the relevant specialist.
5. New or worsening lymphoma red flags at any point in this pathway (persistent/asymmetric salivary gland swelling, palpable purpura, unexplained lymphadenopathy, monoclonal gammopathy, B symptoms): stop routine disease-activity assumptions and pursue urgent further investigation — this always takes priority over continuing to titrate the current regimen.^[2][6]
6. Severe hypokalemia or muscle weakness from distal renal tubular acidosis: urgent assessment and potassium/bicarbonate correction, with potassium citrate as the preferred long-term agent once acutely stabilized.
7. Refractory, severe systemic disease despite hydroxychloroquine, methotrexate, and a rituximab course: sequential or combination biologic therapy (for example, rituximab followed by belimumab) has been studied in refractory disease and may be discussed by a rheumatologist in a specialized or research setting — this remains an investigational strategy, not a standard next step, and should be framed to the patient as such.

• Treating Sjögren disease as though it were simply "severe dry eyes and dry mouth" and missing the fatigue, arthralgia, and lymphoma-risk dimensions that define it as a systemic disease.^[1]
• Dismissing new or persistent salivary gland swelling, palpable purpura, unexplained lymphadenopathy, or B symptoms as routine disease activity rather than recognizing them as lymphoma red flags requiring further workup.^[2][6]
• Promising a patient that hydroxychloroquine will improve their dryness — the best available randomized trial evidence does not support that specific claim, even though the drug remains a reasonable trial for systemic/fatigue symptoms.^[7]
• Assuming rituximab or another biologic is an appropriate next step for sicca symptoms that have not responded to standard measures — current guidelines specifically do not support this, reserving biologic therapy for organ-threatening extraglandular disease.^[8][2]
• Starting rituximab without confirming hepatitis B status first — B-cell depletion carries a real reactivation risk that needs to be screened for and managed proactively.
• Forgetting folic acid co-supplementation when methotrexate is started.
• Missing secondary Sjögren disease in a rheumatoid arthritis or lupus patient who develops new sicca symptoms, and attributing it reflexively to medication side effects or aging instead.
• Applying the adult 2016 ACR/EULAR classification criteria, or adult treatment assumptions, unmodified to a child presenting with recurrent parotitis rather than the classic adult sicca complex.^[2]
• Assuming cevimeline is a routine, accessible Canadian option for Sjögren-associated dry mouth — it is not currently approved or marketed in Canada (see the Dry Mouth chapter for the full detail).
• Discontinuing hydroxychloroquine retinopathy monitoring once a patient has tolerated the drug well for years — retinopathy risk accumulates with duration of use and does not disappear because no problem has occurred yet.
• Overlooking a pregnant, anti-Ro/SSA or anti-La/SSB-positive patient's need for coordinated fetal cardiac monitoring — this risk is real regardless of how mild the patient's own sicca symptoms are.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, pregnancy status, and current guideline-directed monitoring). This table covers what is specific to Sjögren disease's systemic and extraglandular management — see the Dry Eyes and Dry Mouth chapters' own drug tables for the general sicca-management pharmacotherapy (artificial tears, fluoride, antifungals) that applies identically here and is not duplicated. Select any linked drug name to open its complete Pharmasist Drug Database page.

Sjögren-Specific Secretagogues

Full dosing, contraindication, and special-population detail lives in this platform's Dry Mouth chapter and is not repeated here — this row set is limited to what is specific to prescribing in confirmed Sjögren disease.

Immunomodulatory Therapy for Systemic and Musculoskeletal Symptoms

First-line for the fatigue-arthralgia-pain triad; set expectations honestly — this layer treats systemic symptoms, not dryness itself.

Therapy for Severe, Refractory, or Organ-Threatening Extraglandular Disease

Reserved for genuinely severe disease — cryoglobulinemic vasculitis, significant interstitial lung disease, refractory arthritis, lymphoma-associated disease, or disabling neuropathy — not for sicca symptoms alone, which these agents are not indicated for.

Organ-Specific Supportive Therapy

Targets a specific extraglandular complication directly rather than the underlying autoimmune process.